Pathologie

Prof. Dr. Andrea Tannapfel

van der Wijngaart H et al. Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.
Park W et al. Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.
Wu X et al. The mutation of homologous recombination repair genetics is a potential biomarker for immunotherapy in microsatellite stable colon cancer.

Prof. Dr. Thomas Seufferlein

Yoo, HK et al. POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).
Golan T et al. Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
Falchook, GS et al. Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.
Patrick PG et al. Identifying functional loss of ATM gene in patients with advanced cancer.

PD Dr. Florian Roghmann

Lozano R et al. Clinical and molecular characterization study of prostate cancer (PCa) patients with and without previously known germline BRCA1/2 mutations.
Antonarakis ES et al. Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
Barnett E et al. Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC).

Pathologie Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite